Huxley Medical, Inc. today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and commercial release of central sleep apnea (CSA) detection for its SANSA(R) home sleep apnea test.

Discusses Strategic Business Model Pivot and Transition in Sleep Apnea Treatment Approach December 16, 2025 11:00 ...

Blood test results can be overwhelming to digest, complete with medical jargon and numerical values that may not mean much without an accompanying explanation. But to take charge of your health and ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced ...

Eli Lilly hiked its revenue growth guidance by 7%, while Novo Nordisk was forced to slash its targets by ~12%. See why I'm still bullish on LLY stock.

Q4 2025 Earnings Call Transcript December 17, 2025 Veru Inc. beats earnings expectations. Reported EPS is $0.05, expectations ...

I do not swallow eight spiders a year in my sleep, and neither does anyone else. The familiar statistic survives as a viral ...

Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an accep ...

Over 70 million Americans wear digital activity trackers (DATs) to record their sleep, steps and heart rate. A new study from ...

Huxley Medical, Inc. announced the SANSA(R) home sleep apnea test has received regulatory clearance from the United States Food and Drug Administration (FDA) to be used as a diagnostic ECG monitor, ...

A new study published in npj Aging provides compelling evidence that untreated obstructive sleep apnea (OSA) accelerates ...

Obstructive sleep apnea, or OSA, let’s start with the definition. It’s a sleep problem where someone has recurrent episodes ...